Real-World Data Solutions | Real-World Studies
PROSPECTIVE Studies
Generate real-world evidence that reflects how health and disease unfold over time
Design and execute prospective, longitudinal studies that capture multimodal data directly from individuals, including symptoms, behavior, and outcomes beyond clinical settings.
Design publication-ready real-world studies
- Define endpoints aligned to regulatory, payer, or scientific goals
- Capture multimodal data directly from individuals over time
- Structure studies for publication and external scrutiny
Start with an engaged, ready-to-study population
- Start with deeply characterized populations
- Avoid cold-start recruitment and site-based models
- Sustain long-term follow-up without site burden
Execute studies quickly and at scale
- Rapidly enroll observational cohorts
- Maintain strong engagement and data completeness over time
- Deliver structured, analysis-ready datasets
The Evidation Community: an ongoing connection to 5M people
*Varies by population, protocol, and length of program; many of our recent programs have seen 90%+ engagement
**Conversion rate for “click to read” offers once offer is seen
Scaled
- 1M+ Members have participated in research
- 97% of U.S. zip codes represented
Characterized
- 1.3B+ data points collected daily
- 100+ conditions represented
Engaged
- 90% average program engagement*
- 89% average response to content seen in app**
How you run real-world studies with Evidation
Design and execute prospective, longitudinal studies that capture multimodal data directly from individuals over time.
Rapid recruitment from our highly-characterized, responsive health community— meeting specific inclusion/exclusion criteria
Seamless participant experience and onboarding with integrated eConsent and ongoing engagement
Low-burden, active and passive data capture from participants, aligned to study schedules and real-world behavior
.webp)
Ongoing participant support with intuitive, easy-to-understand resources and sustained engagement over time
See how we drive success for our customers:
Identifying and addressing gaps in the patient experience
Myovant uncovered significant unmet needs among individuals with uterine fibroids (UF) in a direct-to-patient 4-month study with 350 women living with UF.
- 92% weekly survey completion
- 85% daily survey completion
Improving blood pressure in overweight individuals through a digital self-management program
Omada ran a pilot study managed by Evidation to demonstrate the value of a digital hypertension self-management program by quantifying its impact on blood pressure control. As a result of this study, Omada was able to publish evidence that their app improves blood pressure and medication adherence.
- 151 individuals with hypertension recruited from the Evidation Community
FluSmart participants receive alerts and nudges to seek care
In partnership with BARDA, Evidation developed and deployed a flu monitoring program, FluSmart, within the Evidation Community to collect rich, longitudinal data and activate high-risk participants into research and care.
- 200K+ individuals participated in FluSmart
- 90%+ engagement rate
Low-burden, objective assessment of symptoms and disease progression
Evidation partnered with a large pharmaceutical company to conduct a real-world study to create a more complete picture of multiple sclerosis (MS) patients’ experiences by combining data from wearable devices with medical claims and demographics data.
- 500+ individuals with MS recruited from the Evidation Community
- Patients who switched therapies had neuro MRIs 1.5x more often than those on a single therapy
Increasing treatment rates with co-created patient engagement
Evidation partnered with Sanofi to test and refine content and messaging for a Type 2 diabetes flu vaccine education program.
- 10K individuals recruited from the Evidation Community
- Up to 2x increase in vaccination rates for participants who engaged with customized diabetes campaign vs. those who engaged with generic messaging
Developing an early warning algorithm for individuals at high risk for COVID-19
Evidation conducted a study to demonstrate that person-generated health data, including data from smartphones and wearable devices, has the potential to enable applications ranging from individual-level early warnings or population-level hotspot detection for COVID-19.
- 800+ individuals recruited from the Evidation Community
80% compliance with study activities
Rapid enrollment of representative population in COVID-19 research
Evidation partnered with a leading pharmaceutical company to build a patient engagement program focused on COVID-19 that engages a representative population across the United States.
- 100K individuals enrolled into research program in 5 weeks
- 90%+ program engagement
- 1.5K of those participants recruited into real-world evidence study in 2 weeks
Measuring cognitive impairment with direct-from-patient real-world data
Evidation partnered with Eli Lilly to develop new endpoints and identify digital signals of cognitive impairment through the use of digital and wearable devices, mobile apps, and sleep sensors.
- 16TB of multimodal data collected over 12 weeks
- 1K+ features extracted from participant behaviorgrams
Better Understanding of the Metamorphosis of Pregnancy (BUMP)
Evidation partnered with 4YouandMe to provide a platform to manage data collection, processing, and storage for the BUMP longitudinal feasibility study aimed to gain a deeper understanding of the pre-pregnancy and pregnancy symptom experience using digital tools.
- 1K participants targeted for enrollment onto the platform
Developing more successful digital health programs with patient perspectives
Evidation partnered with Sanofi to get data-driven insights to prioritize program features and future development of a connected ecosystem for managing type 2 diabetes (T2D).
- 114 insulin-dependent adults with T2D recruited from the Evidation community
- Recruitment completed in 3 weeks
Demonstrating improved quality of life and activity levels in PNH patients
Evidation partnered with a leading pharmaceutical company to conduct a 32-week direct-to-participant study with paroxysmal nocturnal hemoglobinuria (PNH) patients to characterize patient experiences while using a C5 inhibitor.
- 30+ individuals diagnosed with PNH and taking a specific therapy
80% compliance with study activities